Pt Bundamedik Tbk · IDX:BMHS
Pt Bundamedik Tbk — Q1 2024 Earnings Presentation
24 slides from Pt Bundamedik Tbk's earnings presentation, May 2024
Slide 1: PT Bundamedik Tbk Analyst Meeting – 1Q24 Results
PT Bundamedik Tbk Analyst Meeting – 1Q24 Results May 2024 Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary
Slide 2: Leading Provider in Specialized Healthcare Services since 1973
Leading Provider in Specialized Healthcare Services since 1973
Slide 3: Bundamedik Tbk (BMHS) Ecosystem
Bundamedik Tbk (BMHS) Ecosystem Expanding Presence RSIA Az Zahra 10 HOSPITALS Women & Children Hospitals 12 IVF CLINICS PADANG PONTIANAK BATAM 26 LABORATORIES Bunda Hospitals PALEMBANG MAKASSAR CLINICS NETWORK 1k++ (KLINIK PINTAR) YOGYAKARTA 126 FERTILITY CLINICS NETWORK (KFI) Jakarta Depok BANDUNG
Slide 4: 1Q24 Key Highlights
1Q24 Key Highlights 1 2 Consol Revenue New Hospitals +6% +7% +56% Net Revenue vs 4Q23 vs 1Q23 vs 1Q23 +2% # of Outpatients +2957% +18% +9% +2% # of IP Days # of Surgeries +39% +17pps +11% EBITDA improvement EBITDA Margin +29% # of Lab Tests +43% vs 1Q23 improvement vs 1Q23 3 Growing IVF cycles 10% v
Slide 5: 1Q24 Results
@punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 6: Financial & Operational Performance
Financial & Operational Performance HIGHLIGHTS OF CONSOLIDATED RESULT Key Notes 4Q23 1Q24 QoQ (%) YTD Mar 23 YTD Mar 24 YoY (%) 1 OPERATIONALS ('000) 1 Core Business in 1Q24 # Outpatient 154,9 158,4 2% 133,9 158,4 18% • Hospitals metrics: Overall positive growth in #Outpatients, #IP Admission, # Inp
Slide 7: Hospitals Volume
Hospitals Volume # OUTPATIENTS # IP ADMISSION +10% +18% +18% +25% +48% 148.4 154.9 158.4 +92% 11.4 11.3 12.3 133.9 128.3 9.8 10.0 565.6 42.5 485.7 34.4 383.1 359.6 390.5 22.1 21.3 21.3 2019 2020 2021 2022 2023 1Q23 2Q23 3Q23 4Q23 1Q24 2019 2020 2021 2022 2023 1Q23 2Q23 3Q23 4Q23 1Q24 # IP DAYS # SUR
Slide 8: Financial Performance
Financial Performance Consolidated REVENUE EBITDA Core Revenue (Rp B) EBITDA Margin (Rp B,% Margin) Covid Revenue Non-Core EBITDA Core EBITDA 51% +12% 451 25% 419 24% 414 4% 385 20% 26% 18% 266 +33% 96% 100% 100% 74% 90 100% 132 7 59 60 71 53 73 83 1Q20 1Q21 1Q22* 1Q23 1Q24 1Q20 1Q21 1Q22* 1Q23 1Q24
Slide 9: Balance Sheet
Balance Sheet Remains healthy CASH VS DEBT NET DEBT-TO-EBITDA (Rp B) (x) Net 418 -135 -216 225 405 454 Debt 2.2x 1.027 1.062 1.9x 2.0x 830 855 0.7x 625 613 629 622 608 518 490 100 -0.6x -0.4x 2019 2020 2021 2022 2023 1Q24 2019 2020 2021 2022 2023 1Q24 AR Days WORKING CAPITAL DAYS Inventory Days 58 5
Slide 10: IVF Cycles
IVF Cycles Higher Contribution from Outside Jakarta Customers # OF IVF CYCLES (‘000) 1.59 1.55 10% Growth in 1Q24 1.53 1.54 1.41 1.39 1.38 1.39 1.36 1.29 1.26 1.18 1.14 58% 56% Jakarta 60% 60% 57% 55% 53% 51% 57% 52% 54% 58% 54% Outside 42% 44% 49% 40% 40% 43% 43% 45% 47% 48% 46% Jakarta 42% 46% 2Q2
Slide 11: Diagnos: Focusing on genomic testing
Diagnos Focusing on genomic testing Covid # OF TESTS (‘000) 239 Non Covid 265 170 214 20% 11% 228 766 888 686 +43% 172 175 176 1% 23% 35% 22% 163 YoY Non Covid 32% 4% 2% 1% 481 Test Volume 8% 5% 89% 99% 31% 99% 77% 96% 65% 80% 92% 95% 98% 68% 78% 69% 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2020
Slide 12: Strengthening Our Core
Strengthening Our Core @punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 13: Strengthening Our COEs
Strengthening Our COEs GynROSE Clinic Robotic Surgery Bunda Neuro Center Eras NICU/PICU Laparoskopi Bunda Health Center RSM Oncology Bunda General Hospital Bunda Women & Children Hospital Jakarta Klinik Tumbuh Kembang Anak Bunda Endoscopy Center
Slide 14: Update Hospitals Result Initiatives
Update Hospitals Result Initiatives Revenue Per payor: 1Q23 1Q24 Hospitals improvement perspective: • Increased +1pps in Corporate and Insurance 20% payor align with our initiatives BPJS 22% • Bunda well-known for OBGYN and Pediatric 40% 41% OOP specialization, this year we grow other COEs Corp & In
Slide 15: Ensuring Standardized Quality Process
Ensuring Standardized Quality Process
Slide 16: 2024 Update & Initiatives
2024 Update & Initiatives @punva fp Piagnes | morvieyi «= SSBGP Paiccunic ERE OBO Pax, Ts, SEYNCA
Slide 17: Our New Hospitals Performance
Our New Hospitals Performance 172 60++ 2 1 Beds Specialist Doctors W&C Hospitals General Hospital Core Net Revenue EBITDA Financial optimization • +56% net revenue and EBITDA grew from 24,721 4,448 145Bn to 4,448Bn from 1Q23 to 1Q24 • In line with our expectations, 1Q24 reached positive EBITDA +56%
Slide 18: Annualized Cost Efficiency
Annualized Cost Efficiency BPJS Update Identified potential improvement With intensive quality and cost control for BPJS services, update from two of our hospital result in before and after improvement in our Gross Margin 1Q24 Initiative in 3 hospitals Before 1Q24 Improvement Rp 1.5 Bn initiative Co
Slide 19: Annualized Cost Efficiency
Annualized Cost Efficiency Key value Identified potential improvement ✓ Cost transformation saving 1Q24 Initiative Annualised Initiative • 5-10% cost saving per specific specialization through purchase medical Rp 1.9 Bn Rp 7.6 Bn equipment, negotiation, and formulary change Cost Efficiency Cost Effi
Slide 20: 2024 Key Focus Area
2024 Key Focus Area Expansion of our Center of 1 2 Engage in more Corporate and Excellence (COE) and Product of Insurance partnerships Excellence (POE) Key Focus Area 2024 Improve core functions to 5 3 Ramp up the performance of achieve operational our newly acquired hospitals excellence 4 Focusing
Slide 21: 2024 Initiatives Update
2024 Initiatives Update Key Focus Area Expansion of our COE and POE Engage in more Corporate and Insurance partnerships
Slide 22: Morula 2024 Initiatives
Morula 2024 Initiatives Action plan Increase New Female Patients ✓ Attract good quality New Female Patients Acquisition ✓ Patient Profiling and Segmentation ✓ Initiate Team Doctor Programs Improve Doctor Productivity ✓ Acquisition and Development of Top Doctors ✓ Seamless patient journey Improve Qua
Slide 23: ~74K Transactions
219.780 (Existing Non-BPJS Patients) As of 31 March 2024, 41% Of existing Bunda's patients (non BPJS) have registered and used OneBunda Most Frequently Used Features is Janji Temu that generate ~74K Transactions 89.120 OneBunda’s Unique Users
Slide 24: THANK YOU
THANK YOU Disclaimer: Presentation are intended for educational purposes only and do not replace independent professional judgement. Statements of fact and opinions are those of the participants individually and, unless expressly stated to the contrary. Specific data in this presentation was obtaine